Parp Inhibitor Biomarkers Market Regional Analysis

PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023

Code : CMI3762

Pages :176

Formats :

Excel and PDF

Industry : Clinical Diagnostic

Regional Analysis

Global PARP Inhibitor Biomarkers Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global PARP inhibitor biomarkers market over the forecast period. North America is estimated to hold 40.1 % of the market share in 2023. The global PARP inhibitor biomarkers market is expected to witness significant growth in the coming years, driven by the high prevalence of Cancer, favorable health reimbursement, and increased awareness, North America to emerge as the leading region for the PARP Inhibitor Biomarkers market. For instance, according to the press release in February 2020, by imaware, provides laboratory testing for wellness monitoring, informational, and educational use in North America, announced the launch of the At-Home Cancer Screening Test, designed by healthcare company Micro drop. The imaware test for Cancer uses just a few drops of blood to detect unique biomarkers as well as two additional biomarkers to provide more comprehensive results. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced Cancer treatments, are fueling the Cancer market in North America.

Geographies Covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa